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In this retrospective study, we analyzed 17 patients presenting with pulmonary fibrosis and
a positive ANCA testing. This group was compared with a control group of 12 patients with
IPF and negative ANCA testing. Patients were 15 males and 2 females, with a mean age of
66 years. Eight patients were past smokers, 3 current smokers and 6 non-smokers. Lung func-
tion tests at diagnosis were as follows (% predicted): total lung capacity 73% 18, vital capac-
ity 82%  23, forced expiratory volume in 1 s (FEV1) 88%  24, carbon monoxide diffusion
capacity of the lung 49% 2 (% predicted). Bronchoalveolar lavage results showed an increased
cellularity with increased neutrophils counts. High resolution computed tomography of theneumologie, Hoˆpital Bichat-Claude Bernard, 16 rue Henri Huchard, 75018 Paris, France. Tel.: þ331 40
h.aphp.fr (B. Crestani).
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ANCA and pulmonary fibrosis 1393chest showed prominent fibrosis with some degree of ground-glass attenuation in all patients.
These characteristics were similar to the control group. Microscopic polyangiitis (MPA) was
a major complicating event in ANCA-positive patients, occurring in 7 patients (anti-myeloper-
oxidase specificity in 5 patients). Pulmonary fibrosis predated occurrence of MPA in 6 patients
and was diagnosed concomitantly with MPA in 1 patient. During the follow-up, 10/17 patients
died. The death was directly related to vasculitis in 3 patients. We conclude that patients with
pulmonary fibrosis should be evaluated for the presence of ANCA. Patients with positive ANCA
testing, particularly if anti-myeloperoxidase, should be carefully monitored to detect the oc-
currence of microscopic polyangiitis.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
The coexistence of pulmonary fibrosis and antineutrophil
cytoplasmic autoantibodies (ANCA)-positive vasculitis, es-
sentially microscopic polyangiitis (MPA) and rapidly progres-
sive glomerulonephritis has been consistently reported in
case reports or small series.1e8 Classically, ANCA have been
associated with different lung diseases, mostly vasculitides
with pulmonary involvement: Wegener’s granulomatosis
(WG), Churg and Strauss syndrome, and MPA. Pulmonary
fibrosis has already been observed in pathologic series of
ANCA-associated lung diseases.9e11 However, the possible
link between pulmonary fibrosis, ANCA positivity, and vascu-
litis remains poorly understood.
The aim of this study was to collect cases of patients
with pulmonary fibrosis and a positive ANCA testing, and to
describe their clinical, radiological, functional and patho-
logical characteristics.
Methods
Selection of patients
This retrospective study was conducted in 6 universitary
pulmonology French departments with an expertise in the
field of interstitial lung disease, which were asked to
identify from their files patients with pulmonary fibrosis
and positive ANCA testing. A search for ANCA is commonly
performed in French respiratory departments as part of the
diagnostic work up to search for an underlying auto-
immune disease in patients with idiopathic interstitial
lung diseases, as suggested by the international consensus
statement on idiopathic pulmonary fibrosis.12 To be in-
cluded in the study, the following criteria had to be met:
(1) presence of a diffuse parenchymal lung disease with sig-
nificant pulmonary fibrosis on CT scan, defined as reticular
opacities with peripheral and basal predominance, hony-
combing, architectural distortion and/or traction bronchi-
ectasis or bronchiolectasis; focal ground-glass opacities
and/or areas of alveolar condensation may be associated.
(2) Positive ANCA testing.
Patients with connective tissue disease, or with
a diagnosis of other interstitial lung diseases, such as
drug-induced interstitial lung disease, pneumoconiosis,
hypersensitivity pneumonitis, or sarcoidosis, were excluded
from the study. Patients who received a treatment
previously associated with ANCA positivity (such aspropylthiouracyl, carbimazole, minocycline, allopurinol)
were excluded from the study.
Reference group
A group of 12 patients (10 males, 2 females) with
idiopathic pulmonary fibrosis (IPF, defined according to
the ATS/ERS criteria) and a negative ANCA testing were
identified in Bichat hospital and served as a reference
group (ANCA-negative patients). A surgical lung biopsy
was performed in 3 ANCA-negative patients and showed
a UIP pattern. Mean age of these patients at diagnosis was
66 12 years. Ten of them were smokers (1 current, 9
past). Mean cumulative tobacco exposure in smokers was
39 16 pack.years. ANCA-negative patients were tested
for ANCA 1e4 times during the follow-up period (1,
nZ 4; 2, nZ 6; 3, nZ 1; 4, nZ 1) and were always found
negative. The mean time of follow-up was 50 33
months.
Data collection
Characteristics of the patients were recorded from the
medical files and the following items were analyzed:
epidemiological characteristics (age, sex, smoking history,
environmental exposure), date of pulmonary fibrosis di-
agnosis, date of first positive ANCA testing, associated
diagnosis including MPA. Microscopic polyangiitis was de-
fined according to the criteria of the Chapel Hill consensus
conference.13 The results of high resolution computed to-
mography (HRCT) of the chest, pulmonary function tests
(PFTs), and bronchoalveolar lavage (BAL) obtained at the
time of the diagnosis of pulmonary fibrosis were analyzed.
HRCTs were reviewed by 2 radiologists (MPD, MB), who as-
sessed a quantitative quotation for the presence of
ground-glass opacities and fibrosis, according to Kazerooni
and colleagues.14
The outcome of the patients was analyzed concerning
length of follow-up, survival, clinical, functional and
radiological evolution, with a particular attention to alve-
olar hemorrhage or MPA occurrence.
Statistical analysis
All data are expressed as means and standard deviation
(SD). Because of the small population size, statistical
comparisons used non-parametric tests: the ManneWhitney
1394 G. Foulon et al.U test and the Wilcoxon test, for unpaired and paired data,
respectively. We compared the survival of ANCA-negative
IPF patients and ANCA-positive pulmonary fibrosis patients
with the KaplaneMeier method. P-values< 0.05 were con-
sidered statistically significant.Results
Patients
Seventeen patients (15 males, 2 females) with pulmonary
fibrosis and positive ANCA testing were included in this
study. Their mean age at diagnosis of pulmonary fibrosis
was 66 11 years. A surgical lung biopsy was obtained in 3
ANCA-positive patients and showed a UIP pattern with no
evidence of vasculitis. Eight patients were past smokers,
3 current smokers and 6 non-smokers. Mean cumulative to-
bacco exposure in smokers was 52 37 pack.years.Table 1 Clinical characteristics of the ANCA-positive and ANCA
Gender Age at
diagnosis
(years)
Smoking
status
Smoking
history
(pack.years)
ANCA specificity Tre
ANCA-positive patients
1 M 84 Past 70 Lactoferrin S,
2 M 58 Past 60 Myeloperoxidase S,
3 M 82 Past 100 Myeloperoxidase S,
4 M 65 Past 3 Myeloperoxidase S,
5 M 59 Current 80 Unidentified No
6 F 73 Past 120 Unidentified S,
7 M 55 Current 35 Unidentified S
8 M 67 Past 20 Unidentified S
9 M 55 Current 37 Unidentified A
10 M 59 Never 0 Myeloperoxidase S
11 M 68 Never 0 Myeloperoxidase S,
12 M 45 Never 0 Unidentified S,
13 F 64 Never 0 PR3 S
14 F 82 Never 0 Unknown S
15 M 75 Past 27 Elastase S,
16 M 72 Never 0 Unidentified No
17 M 66 Past 20 Myeloperoxidase S,
ANCA-negative patients
1 M 50 Current 25 NA Co
2 M 67 Past 40 NA S,
3 F 75 Never 0 NA S,
4 M 63 Past 30 NA S
5 M 71 Past 35 NA No
6 M 78 Past 50 NA No
7 M 58 Past 60 NA No
8 M 55 Past 20 NA S,
9 M 78 Past 30 NA No
10 M 46 Past 35 NA S,
11 M 73 Past 70 NA S
12 F 80 Never 0 NA NA
PR3: proteinase 3; NA: not applicable; S: corticosteroids; C: cyclophos
infliximab; NAC: N-acetyl cysteine; U.C.: unknown cause; LFE: lung fib
cell lung cancer; and ARF: acute respiratory failure.The mean time of follow-up was 57 41 months. One pa-
tient was lost to follow-up 12 months after diagnosis of pul-
monary fibrosis.
Characterization of antineutrophil cytoplasmic
antibodies
ANCA were of perinuclear fluorescence in 14 patients and of
cytoplasmic fluorescence in 3 patients. ANCA specificity
was tested by ELISA in all patients (Table 1). ANCA specific-
ity was identified in 9 patients: anti-myeloperoxidase in 6
patients, anti-lactoferrin, anti-elastase and anti-proteinase
3 in 1 patient each. In 8 patients, no specificity was
identified.
In 3 patients, ANCA were found to be positive at the time
of pulmonary fibrosis diagnosis. In 1 patient, ANCA were
tested negative at diagnosis and became positive 16 months
after diagnosis. In 13 patients, ANCA not screened at the
time of pulmonary fibrosis diagnosis and were found-negative patients
atment Vasculitis Length of
follow-up
(months)
Outcome
C Lung, skin, kidney 61 Died, vasculitis
A None 53 Alive
C Lung, kidney 53 Died, U.C.
C Lung, kidney 98 Died, U.C.
ne None 24 Lost to follow-up
Inf None 23 Died, SCLC
None 38 Died, LFE
None 42 Died, LFE
None 71 Alive
Neuropathy, muscle 44 Alive
I Lung, kidney 21 Died, vasculitis
A, C Lung, skin 165 Died, U.C.
None 9 Died, ARF
None 29 Alive
NAC None 30 Alive
ne None 71 Alive
C Lung, kidney 130 Died, vasculitis
None 111 Alive
A None 38 Died, LFE
A, O, I None 19 Died, LFE
None 113 Alive
ne None 19 Died, NSCLC
ne None 42 Died, U.C.
ne None 75 Alive
A, C, Inf None 40 Alive
ne None 41 Alive
C, Inf, NAC None 33 Alive
None 50 Alive
C None 18 Alive
phamide; A: azathioprin; Co: colchicine; Inf: interferon gamma; I:
rosis exacerbation; SCLC: small cell lung cancer; NSCLC: non-small
Table 3 Bronchoalveolar lavage cell counts at diagnosis
ANCA-positive
patients
(nZ 15)
ANCA-negative
patients
(nZ 12)
P-value
Cells (/ml) 315 167 194 146 0.04
Macrophages (%) 66.4 24.0 67.7 14.5 NS
Neutrophils (%) 21.0 20.6 16.8 15.0 NS
Eosinophils (%) 4.6 5.9 4.1 3.9 NS
Lymphocytes (%) 6.3 6.0 10.8 11.2 NS
Siderophages (%) 22.9 28.7 22.3 31.8 NS
ANCA and pulmonary fibrosis 1395positive 23 36 months (range: 2e137 months) after pul-
monary fibrosis diagnosis.
Evaluation of lung fibrosis at diagnosis
The pulmonary function parameters at diagnosis are listed
in Table 2. For 1 patient, results were not available. A re-
strictive ventilatory defect, as shown by reduced total
lung capacity below 80%, was found in 10 out of 16 tested
patients. An obstructive ventilatory pattern was never ob-
served. DLCO was reduced in all tested patients (16/16).
The carbon monoxide transfer coefficient (KCO) was re-
duced in 14/16 patients. A mild hypoxemia at rest was mea-
sured in 9 patients.
Analysis of BAL cytological analysis (Table 3) was avail-
able in 15 patients. An increased total cell count
(>250,000 cells/ml) was found in 9 patients out of 15 pa-
tients. Differential counts disclosed a prominent neutrophil
alveolitis (>5%) in 13/15 patients and increased eosinophils
(>5%) in 4/15 patients. Evidence of microscopic alveolar
hemorrhage (defined as more than 20% siderophages in
BAL) was observed in 7/15 patients.
HRCT analysis showed honeycombing, reticular intra-
lobular opacities and traction bronchiectasis in all the
patients. Fibrotic changes predominated in the lower
and/or middle lobe(s) and in the subpleural areas in all
cases. Some degree of ground-glass attenuation was pres-
ent in all the patients but was usually limited. In 2 patients,
ground-glass opacities were the prominent abnormality.
Air-space consolidation was rare (3 patients). A quantita-
tive quotation for the presence of ground-glass opacities
and fibrosis, according to Kazerooni and colleagues,14 was
performed when the quality of the HRCT was considered
suitable and is reported in Table 2.
Comparison with the reference group
At diagnosis, all lung function tests analyzed, BAL values
and HRCT scores were similar in ANCA-positive and ANCA-
negative patients (Tables 2 and 3).Table 2 Pulmonary function tests and HRCT scores at
diagnosis
ANCA-positive
patients
(nZ 17)
ANCA-negative
patients
(nZ 12)
P-value
TLC (% predicted) 73.6 18.1 77.1 8.3 NS
VC (% predicted) 82.1 23.0 84.4 13.2 NS
FEV1 (% predicted) 88.3  24.0 85.2 19.1 NS
DLCO (% predicted) 49.4 20.0 49.9 14.5 NS
PaO2 (mmHg) 79.0 13.7 70.2 12.2 NS
PaCO2 (mmHg) 37.1 4.5 38.7 5.0 NS
Ground-glass score 1.44 0.89
(nZ 10)
1.16 0.52
(nZ 11)
NS
Fibrosis score 2.16 0.45
(nZ 12)
1.95 0.76
(nZ 12)
NS
TLCZ total lung capacity; VCZ vital capacity; FEV1Z forced
expiratory volume at 1 s; and DLCOZ diffusion capacity for car-
bon monoxide.Microscopic polyangiitis occurrence
MPA was a major event in this cohort of ANCA-positive
patients and was not observed in ANCA-negative patients.
MPA was diagnosed in 7/17 patients (41%). In most patients
(6/7), MPA developed after pulmonary fibrosis assessment,
with a mean delay of 53 months (range: 15e137 months). In
only 1 patient, the diagnosis of pulmonary fibrosis and MPA
was concomitant (Table 4).
MPA involved lung, skin and kidney in 1 patient, lung and
kidney in 4 patients, lung and skin in 1 patient, peripheral
nervous system and muscle in 1 patient. Lung involvement
consisted of alveolar hemorrhage, either macroscopic (5/6)
or microscopic (1/6). Vasculitis was histologically confirmed
in 6/7 patients (kidney biopsy: 4 patients; skin biopsy: 1
patient; muscle biopsy: 1 patient). In 1 patient, vasculitis
was not histologically confirmed but the diagnosis of MPA
was assessed by the occurrence of alveolar hemorrhage and
acute renal failure leading to death despite high-dose
steroid treatment, mechanical ventilation and
haemodialysis.
Anti-myeloperoxidase antibodies are associated
with microscopic polyangiitis occurrence in
patients with pulmonary fibrosis
In patients who developed MPA, ANCA were of anti-
myeloperoxydase specificity in 5, anti-lactoferrin specific-
ity in 1, and without identified specificity in 1. MPA
occurred in 5/6 of the anti-myeloperoxydase positive
patients (Table 4). The detection of ANCA positivityTable 4 Relative timing of fibrosis diagnosis, ANCA posi-
tivity detection and vasculitis occurrence in the 7 patients
with vasculitis
Patients Time between fibrosis
diagnosis and ANCA
detection (months)
Time between fibrosis
and vasculitis occurrence
(months)
1 2 57
3 20 20
4 26 0
10 0 15
11 19 19
12 137 137
17 13 69
1396 G. Foulon et al.preceded the occurrence of MPA in 3/7 patients (by 15, 55
and 56 months). In 3/7 patients, ANCA positivity was de-
tected at the time of MPA diagnosis, but had not been
searched before. In 1 patient, ANCA were negative at diag-
nosis of MPA and became positive 26 months later.
Outcome
During the follow-up period, 10/17 patients died. As
assessed with the KaplaneMeier method, the 5-year sur-
vival was 60% (Fig. 1). Six of the 7 patients with MPA died,
87 53 months after the identification of pulmonary fibro-
sis and 37 37 months after MPA occurrence. The death
was related to the evolution of the vasculitis in 3 patients.
Four of the 10 patients who did not develop MPA died during
follow-up. Acute respiratory failure diagnosed as an exacer-
bation of pulmonary fibrosis occurred in 2 patients (in 1 of
them a BAL performed at the time of exacerbation showed
no evidence of alveolar hemorrhage). One patient died of
acute respiratory failure of unknown origin. The 4th patient
died with disseminated small cell lung cancer. Survival was
similar in the ANCA-positive group and the reference group
(Fig. 1).
Discussion
This study describes the clinical, radiographical and func-
tional characteristics of a group of 17 patients with
pulmonary fibrosis and positive-ANCA testing, and identifies
the development of small vessels vasculitis as a major
complication. This is the first study to compare the clinical
presentation of patients with ANCA-positive fibrosis with
a control group of ANCA-negative fibrosis. Our results
demonstrate that at diagnosis, the clinical, radiographical,
and bronchoalveolar lavage data are similar, thus empha-
sizing the need to systematically evaluate the presence of
ANCA in patients with idiopathic fibrotic lung diseases.0 20 40 60 80 100 120
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Figure 1 KaplaneMeier survival curve for patients according
to the ANCA status. Dotted line: ANCA-positive patients; full
line: ANCA-negative patients. Survival was similar in both
groups (PZ 0.65).In the literature, small case series, reported the associ-
ation of lung fibrosis with MPA or rapidly progressive
glomerulonephritis in patients with ANCA with an anti-
myeloperoxidase specificity.1e8 In most cases, lung fibrosis
preceded the development of pulmonary vasculitis by 1e
10 years, or the 2 diseases were diagnosed concomitantly.
More recently, Homma and colleagues15 described a group
of 31 patients with ANCA and fibrotic lung disease, either
idiopathic or connective tissue diseases-associated. Chest
CT showed honeycombing in 26/31 patients. MPA occurred
in 8/31 patients. Pathology of the lung was available in 15
patients, and showed usual interstitial pneumonia in 11 pa-
tients, non-specific interstitial pneumonia in 2 patients,
and vasculitis in 5 patients.
The high prevalence of pulmonary fibrosis seems to have
been overlooked in older series of ANCA-associated vascu-
litis. When analyzing lung samples from patients with
ANCA-associated lung disease (essentially Wegener’s
disease and Churg and Strauss syndrome) obtained with
surgical biopsy or at autopsy, Gaudin and colleagues noted
the presence of an interstitial fibrosis in 13/27 patients,
predominantly in patients with c-ANCA.9 Similarly, some
degree of lung fibrosis was observed in 11/15 patients in
one series11 and in 4/9 patients in another series.10 The
high prevalence of lung fibrosis in patients with ANCA-pos-
itive vasculitis may be secondary to repeated episodes
of lung injury, either clinically occult or clinically evident,
or may point to the inducing role of pulmonary fibrosis on
the development of vasculitis. The latter hypothesis is sup-
ported by the evidence that fibrosis usually precedes the
development of vasculitis in our series, and in previously
reported series.15
The current study has some limitations. As it is a retro-
spective study, there may be a recall bias with identification
of the ANCA-positive patients with vasculitis; this bias may
contribute to the high frequency of patients with vasculitis
in this series. Furthermore, lung biopsy was obtained only in
3 patients; therefore, the underlying fibrotic lung disease
was not precisely characterized in most of the patients.
However, on the basis of the ATS/ERS diagnosis criteria,12
most of the ANCA-positive patients (12/17) would have
been classified as probable IPF and certain IPF in 3 cases
who benefited of lung biopsy with UIP. Two patients had
prominent ground-glass opacities at diagnosis with honey-
combing and IPF was considered possible; lung biopsy was
not available in these patients. The reference group was
from 1 centre only (Bichat hospital) but appeared to be
well matched with the ANCA-positive patients group on
the basis of age, sex, and lung function tests at diagnosis.
Idiopathic pulmonary fibrosis (IPF), the most common
form of idiopathic fibrotic lung diseases, has been associ-
ated with the production of circulating IgG autoantibodies
to antigen(s) that are associated with alveolar lining
cells,16,17 and there is evidence for a local humoral immune
response associated with B-lymphocyte aggregates in the
IPF lungs.18 However, there is a debate as to whether these
antibodies are epiphenomenal and a secondary feature of
tissue damage induced by some other mechanism, or a con-
tributing factor to the ongoing fibrotic process.19 Interest-
ingly, autoimmunity was recently shown to be central in
non-specific idiopathic pneumonia,20 the second most fre-
quent fibrotic lung disorder.
ANCA and pulmonary fibrosis 1397The prevalence of ANCA in patients with IPF has not been
extensively studied. It was estimated to be 9% in a Japanese
series of IPF patients published in an abstract form.21 In Bi-
chat hospital the percentage of ANCA positivity among pa-
tients with IPF was estimated to be 8% (4 among 46
patients seen within 4 years). ANCA could play a pathophys-
iological role in IPF as already shown in vasculitis by activat-
ing neutrophils, monocytes and endothelial cells which are
known to express myeloperoxidase at their membrane. In-
terestingly, airway epithelial cells may also express myelo-
peroxidase22 and may become a target for ANCA. One may
speculate that ANCA may promote chronic lung injury and
contribute to the vicious circle of lung fibrosis.
Tobacco smoke exposure may play an initiating role in
the pathophysiology of the disease. Tobacco smoke may
activate epithelial cells and stimulate their MPO expres-
sion. Furthermore, tobacco smoke exposure is known to
induce a chronic infiltration of neutrophils of lung struc-
tures. Neutrophils are increased in the alveolar space in
most of the pulmonary fibrotic disorders, whatever their
cause. Whether this may contribute to self-immunization to
myeloperoxidase or other neutrophil-associated proteins
and the generation of ANCA with subsequent vasculitis is
unknown. Cumulative tobacco exposure tended to be
higher in ANCA-positive patients than in ANCA-negative
controls, although the difference was not statistically
significant. In this context, it is significant that ANCA-
positive vasculitis may occur in patients with established
bronchiectasis,23 a situation with chronic neutrophilic in-
flammation of the airways.
Interestingly, in patients with rheumatoid arthritis (RA),
ANCA positivity seems to be associated with an increased
incidence of lung fibrosis. Indeed, ANCA are detected in
11%e16% of RA patients, are essentially perinuclear, either
anti-myeloperoxydase or without identified specificity (60%
or more), and are associated with more active disease, with
occurrence of vasculitis, and more extra-articular manifes-
tations such as pulmonary fibrosis.24,25 For example, Cam-
bridge and colleagues24 detected a pulmonary fibrosis in
3/10 ANCA-positive RA25 patients versus 0/87 ANCA-nega-
tive RA patients, whereas Braun and colleagues detected
a pulmonary fibrosis in 5/61 ANCA-positive RA patients ver-
sus 0/324 ANCA-negative RA patients.
In conclusion, we suggest that a search for ANCA should
be performed at diagnosis in every patient with pulmonary
fibrosis as the presence of ANCA will increase the risk of
development of a vasculitis and promote specific monitor-
ing of the patients, especially if the specificity of ANCA is of
anti-MPO specificity. Further studies with larger groups of
patients are needed to prospectively determine whether
ANCA play a pathophysiological role in fibrotic lung
disorders.
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